KRAS and colorectal carcinoma: There is also increasing evidence that mutated versions of KRAS lead to the development of chemoresistance and that subclones of mutated KRAS are present at the time of diagnosis of CRC even in tumors that are initially identified as wild-type (wt) for KRAS [7].